ALT
NASD Altimmune, Inc.$2.30 ↑ +0.00 (+0.00%) Trading Up from the previous close of $2.30, $0.02 below the day’s high of $2.32
- YTD change
- -36.29%
- vs 20-day SMA
- -15.26%
- vs 200-day SMA
- -31.69%
Price ranges
Price & Performance
-1.26 (-35.39%) / 6M
Signals & Sentiment
Momentum, market sentiment, and recent alerts
- The stock is 99.0% away from all-time highs of $237.30
- ALT is down 36% since the beginning of the year
- ALT is down 43% over the past 12 months
- ALT is down 30% over the past 1 month
- 23% of all ALT investors are betting against ALT
ALT reads not so good: price sits below both the 20- and 200-day averages, the 12-month move is -42.5%.
- Previous minute
- +$0.00
- Last hour
- +$0.00
- Last 5 days
- -10.16%
- vs 8-day SMA
- -4.66%
Financial Strength
Earnings, valuation, and balance sheet
Earnings
Valuation
Balance sheet & scale
Company & Peers
Company profile and competitor comparison
Company profile
Altimmune, Inc. is a clinical stage biopharmaceutical company, which focuses on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. Its lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and NASH. In addition, Altimmune is developing HepTcell, an immunotherapeutic designed to achieve a functional cure for chronic hepatitis B. The company was founded in 1997 and is headquartered in Gaithersburg, MD.
You looked up one stock
Trade Ideas watches them all
Real-time scanning and AI-generated signals across the entire market.
Prices and alerts are delayed by at least 20 minutes. Chart history reflects daily closing prices. Information is provided for research purposes only and is not investment advice.
